Randomized phase II study of erlotinib (ERL) in two different schedules with concomitant modified XELOX in the first-line treatment of metastatic colorectal cancer (mCRC): Correlation with serial serum levels of amphiregulin (AMR) and transforming growth factor receptor-alpha (TGFa)
Other outputs


引用次數
替代計量分析
.

其它資訊
著者Chan ATC, Chan SL, Ho WM, Lau W, Mo F, Hui EP, Chan C, Poon A, Dattatray R, Wong SCC, To KF, King AD, Ahuja AT, Ma B
出版作品名稱Journal of Clinical Oncology
出版年份2013
月份2
卷號31
期次4
出版社AMER SOC CLINICAL ONCOLOGY
頁次425 - 425
國際標準期刊號0732-183X
語言英式英語
Web of Science 學科類別Oncology;Oncology

上次更新時間 2020-21-11 於 02:20